![](https://news.europawire.eu/wp-content/uploads/2016/02/Merck-GROUP-LOGO.png)
First Phase III trial evaluating the addition of an immune checkpoint inhibitor to standard of care in first-line ovarian cancer New investigational regimen will evaluate avelumab in extending progression-free survival in treatment-naïve women Darmstadt, Germany and New York, US, 07-Jul-2016 … Read the full press release